Paratek Still On Target

Paratek saw a major pullback since June, but the fundamentals are unchanged. The major breakout will come if it can get through the blue resistance line, which will happen in teh next year if it can exceed its 2021 high.

Earnings: Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021

Prior posts on PRTK. I came across the stock while researching potential investments in case the U.S. onshores the manufacturing of precursor chemicals and basic medicines following shortages during the intial global lockdown. The company develops new antiobiotics to tackle new and existing diseases. My specualtive assumption is the company will benefit from an onshoring of supply chains because at minimum government grants will increase. The stock will benefit if this investment narrative draws in more investors. The company has deevloepd a new approved drug and aims to be cash flow positive by 2023. If that target holds, the stock-specific downside risk will be minimal from the current level.

American Antibiotic Manufacturer Completed Next Base

Paratek Has Based

American Antibiotics

Prior posts on PRTK. Paratek is looking good here. A break of the $10 level will confirm the completed base. A move through $13 and away it goes.

The first post: Partaking of Paratek. I"m up 100 percent so far, frankly not a terribly impressive return for the past 9 months considering all the money being pumped into the market. I still like the story though: a domestic manufacturer of drugs.

Paratek Extends into Breakout

A week ago I posted Partaking of Paratek. As I discussed in the last post, this company makes antibiotics in the USA. This article is from June 2020.

Fierce Pharma: As U.S. calls for stateside manufacturing, antibiotic maker Paratek gambles on 'onshoring' effort

Paratek Pharmaceuticals, maker of antibiotic Nuzyra, is kick-starting a three-year plan to build a government-funded, second supply chain in the U.S. in an effort to flesh out the nation's strategic supply of pandemic response drugs.

Partaking of Paratek

Another chart winner. Back when Kodak (KODK) announced it won a contract to make pharmaceutical precursors, I went searching for pure-play stocks in this space. I didn't find anything attractive on the public markets. I did come across a company making antibiotics in the USA: Paratek (PRTK).

News out yesterday: Billionaire David Shaw Pours Money Into 3 “Strong Buy” Stocks

Shaw is among those cheering the company. Increasing its stake by 82%, D.E. Shaw bought up 457,341 shares in the second quarter. Following the purchase, the fund’s total PRTK position lands at 1,018,465 shares and is worth $4,267,368.

Writing for H.C. Wainwright, 5-star analyst Ed Arce cites NUZYRA’s performance as a key component of his bullish thesis, noting that the company's therapy is “already on track to be one of the most successful antibiotic launches of the last decade.” The asset is a tetracycline-class antibacterial designed as a treatment for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

I bought this one because I like that they manufacture basic drugs in the USA, plus they have a good basing pattern. There's a lot of resistance up to $10 per share, but the base completes around $6. The real upside would be if it can make it past $10 per share. I only have a starter position in this stock.